The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization.

[1]  Soo-Ho Choi,et al.  Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity , 2011, Circulation research.

[2]  S. Tsimikas,et al.  Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. , 2011, Current pharmaceutical design.

[3]  P. Talmud,et al.  Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. , 2010, Journal of the American College of Cardiology.

[4]  M. Budoff,et al.  Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. , 2010, The American journal of cardiology.

[5]  R. Virmani,et al.  Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. , 2010, Journal of the American College of Cardiology.

[6]  J. Witztum,et al.  The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity , 2008, Current opinion in lipidology.

[7]  S. Tsimikas.  In vivo markers of oxidative stress and therapeutic interventions. , 2008, The American journal of cardiology.

[8]  P. Libby,et al.  Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[9]  M. Boffa,et al.  Lipoprotein(a): a unique risk factor for cardiovascular disease. , 2006, Clinics in laboratory medicine.

[10]  Y. Jang,et al.  Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. , 2005, The American journal of cardiology.

[11]  Antonio Colombo,et al.  Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. , 2005, Circulation.

[12]  B. Strauss,et al.  Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a): Short-Term and Long-Term Immunologic Responses to Oxidized Low-Density Lipoprotein , 2004, Circulation.

[13]  Joseph Juliano,et al.  Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[14]  H. Horiguchi,et al.  Oxidized LDL in Carotid Plaques and Plasma Associates With Plaque Instability , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Renu Virmani,et al.  Morphological Predictors of Restenosis After Coronary Stenting in Humans , 2002, Circulation.

[16]  E. Dennis,et al.  Correlation of Antiphospholipid Antibody Recognition with the Structure of Synthetic Oxidized Phospholipids , 2002, The Journal of Biological Chemistry.

[17]  Pojen P. Chen,et al.  Human-Derived Anti-Oxidized LDL Autoantibody Blocks Uptake of Oxidized LDL by Macrophages and Localizes to Atherosclerotic Lesions In Vivo , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[18]  T. Matsuo,et al.  Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes , 2001, Circulation.

[19]  D. Steinberg,et al.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans? , 2001, Trends in cardiovascular medicine.

[20]  J. Ross,et al.  Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. , 2001, Journal of the American College of Cardiology.

[21]  R. Hegele,et al.  Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. , 2000, American heart journal.

[22]  G. Maurer,et al.  Plasma levels of C-reactive protein after coronary stent implantation. , 2000, European heart journal.

[23]  B. Strauss,et al.  Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. , 1999, Circulation.

[24]  F. Werf,et al.  Malondialdehyde-modified LDL as a marker of acute coronary syndromes. , 1999, JAMA.

[25]  J. Witztum,et al.  Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo , 1999, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[26]  G. Dangas,et al.  Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. , 1998, Journal of the American College of Cardiology.

[27]  W. Edwards,et al.  Histologic correlates of angiographic chronic total coronary artery occlusions: influence of occlusion duration on neovascular channel patterns and intimal plaque composition. , 1997, Journal of the American College of Cardiology.

[28]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[29]  J. Kahn.  Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. , 1993, American heart journal.

[30]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[31]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.